Aripiprazole Tablet
Product Images NDC 68788-7733

Product Visual Gallery

This gallery contains 10 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 68788-7733). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Preferred Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole-fig-16.jpg (Aripiprazole Fig 16)

A Kaplan-Meier curve showing the proportion of subjects with relapse over 182 days from randomization for Aripiprazole versus placebo. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The graph includes lines for Aripiprazole (solid blue) and placebo (dashed red), along with the number of subjects at risk at various time points.*

FDA Label Image

Aripiprazole-fig-17 (Aripiprazole Fig 17)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over 364 days from randomization, for Aripiprazole versus placebo. The graph includes the number of subjects at risk for each group at various time points along the X-axis (Days from Randomization). The Aripiprazole group is shown with a solid line and the placebo group with a dashed line, indicating lower relapse rates in the Aripiprazole group throughout the study period.*

FDA Label Image

Effects Of Other Drugs On Dehydro-aripiprazole (Aripiprazole Fig10)

A pharmacokinetic chart showing fold changes in dehydro-aripiprazole levels (AUC and Cmax) with 90% confidence intervals when co-administered with various inhibitors and inducers, including CYP3A4 inhibitors (ketoconazole), CYP2D6 inhibitors (quinidine), CYP3A4 inducers (carbamazepine), gastric acid blockers (famotidine), and other drugs (valproate, lithium, lorazepam). The x-axis represents change relative to reference without interacting drug.*

FDA Label Image

Effects Of Aripiprazole On Pharmacokinetics Of Other Drugs (Aripiprazole Fig11)

A scatter plot chart displaying fold changes and 90% confidence intervals for pharmacokinetic parameters (DMVDRP, AUC, Cmax, INR) of various drugs relative to a reference without interacting drug. The drugs include dextromethorphan, warfarin, omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, and escitalopram, among others, with data points illustrating how each is affected.*

FDA Label Image

Effects Of Intrinsic Factors On Aripiprazole (Aripiprazole Fig12)

A pharmacokinetic chart showing the fold change and 90% confidence intervals of Aripiprazole under various conditions including CYP2D6 metabolism status, gender, age groups, hepatic impairment levels, and severe renal impairment. The graph plots change relative to reference values for AUC and Cmax parameters.*

FDA Label Image

Effects Of Intrinsic Factors On Dehydro-aripiprazole (Aripiprazole Fig13)

A scatter plot chart illustrating the fold change and 90% confidence interval (CI) of Dehydro-Aripiprazole pharmacokinetics based on variables such as CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and severe renal impairment. Axes represent the change relative to reference on the X-axis and pharmacokinetic parameters (AUC and Cmax) on the Y-axis.*

FDA Label Image

Effects Of Other Drugs On Aripiprazole (Aripiprazole Fig9)

A pharmacokinetic chart depicting Aripiprazole fold change and 90% confidence intervals for AUC and Cmax when co-administered with various inhibitors, inducers, and other drugs relative to a reference without interacting drug. The chart includes effects of CYP3A4 inhibitor ketoconazole, CYP2D6 inhibitor quinidine, CYP3A4 inducer carbamazepine, gastric acid blocker famotidine, and other drugs valproate, lithium, and lorazepam on Aripiprazole exposure.*

FDA Label Image

Aripiprazole Tablets 2mg (Aripiprazole Fig1 New)

Label for Aripiprazole Tablets 2 mg oral tablets by Preferred Pharmaceuticals, Inc. The label states it is generic for Abilify and each tablet contains 2 mg of aripiprazole USP. It includes spaces for package size, expiration date, lot, batch, and prescribing instructions in English and Spanish. Mfg: Ascend Laboratories, LLC is indicated.*

FDA Label Image

Aripiprazole Structure (Aripiprazole Fig8)

Chemical structure diagram of aripiprazole, showing its molecular framework with chlorine atoms and the characteristic bicyclic and piperazine rings.*

FDA Label Image

Aripiprazole-graph (Aripiprazole Graph)

A Kaplan-Meier curve chart showing the proportion of subjects with relapse over days from randomization for Aripiprazole versus placebo. The x-axis represents days from randomization, while the y-axis shows the proportion with relapse. Aripiprazole has a lower relapse proportion compared to placebo. A table below the graph displays the number of subjects at risk over time for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.